Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 1
1979 2
1980 6
1981 5
1982 3
1983 3
1984 5
1985 7
1986 4
1987 16
1988 15
1989 17
1990 10
1991 9
1992 17
1993 15
1994 20
1995 30
1996 32
1997 21
1998 28
1999 28
2000 42
2001 44
2002 71
2003 73
2004 92
2005 123
2006 114
2007 106
2008 170
2009 175
2010 215
2011 244
2012 274
2013 340
2014 388
2015 457
2016 533
2017 496
2018 558
2019 576
2020 715
2021 785
2022 926
2023 911
2024 749

Text availability

Article attribute

Article type

Publication date

Search Results

8,481 results

Results by year

Filters applied: . Clear all
Page 1
Transcriptional landscape of rice roots at the single-cell resolution.
Liu Q, Liang Z, Feng D, Jiang S, Wang Y, Du Z, Li R, Hu G, Zhang P, Ma Y, Lohmann JU, Gu X. Liu Q, et al. Among authors: hu g. Mol Plant. 2021 Mar 1;14(3):384-394. doi: 10.1016/j.molp.2020.12.014. Epub 2020 Dec 19. Mol Plant. 2021. PMID: 33352304 Free article.
Promiscuous G-protein activation by the calcium-sensing receptor.
Zuo H, Park J, Frangaj A, Ye J, Lu G, Manning JJ, Asher WB, Lu Z, Hu GB, Wang L, Mendez J, Eng E, Zhang Z, Lin X, Grassucci R, Hendrickson WA, Clarke OB, Javitch JA, Conigrave AD, Fan QR. Zuo H, et al. Among authors: hu gb. Nature. 2024 May;629(8011):481-488. doi: 10.1038/s41586-024-07331-1. Epub 2024 Apr 17. Nature. 2024. PMID: 38632411
Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial.
Chen YP, Liu X, Zhou Q, Yang KY, Jin F, Zhu XD, Shi M, Hu GQ, Hu WH, Sun Y, Wu HF, Wu H, Lin Q, Wang H, Tian Y, Zhang N, Wang XC, Shen LF, Liu ZZ, Huang J, Luo XL, Li L, Zang J, Mei Q, Zheng BM, Yue D, Xu J, Wu SG, Shi YX, Mao YP, Chen L, Li WF, Zhou GQ, Sun R, Guo R, Zhang Y, Xu C, Lv JW, Guo Y, Feng HX, Tang LL, Xie FY, Sun Y, Ma J. Chen YP, et al. Among authors: hu gq. Lancet. 2021 Jul 24;398(10297):303-313. doi: 10.1016/S0140-6736(21)01123-5. Epub 2021 Jun 7. Lancet. 2021. PMID: 34111416 Clinical Trial.
8,481 results